Through Rights Issue, Pyridam Farma (PYFA) Explores Expansion and Acquisition Potential
JAKARTA, KOMPAS.com - PT Pyridam Farma Tbk (PYFA) is implementing a Capital Increase with Pre-emptive Rights II (PMHMETD II), or rights issue, after obtaining shareholder approval at an Extraordinary General Meeting of Shareholders (EGMS) held in April 2026.
This approval marks an important milestone in the company’s transformation journey to build an integrated healthcare services ecosystem, in line with efforts to enhance competitiveness and create long-term value for shareholders.
In its prospectus, the company plans to issue new shares in a maximum amount of 5.7 billion shares with a nominal value of Rp 100 per share, accompanied by the issuance of warrants in accordance with applicable provisions.
This step is part of the strategy to accelerate expansion and strengthen its position within the integrated healthcare industry ecosystem.
“The company wishes to express its gratitude for the shareholders’ trust. Naturally, with the approval we have received, we will focus on completing our ecosystem. The company views that as a pharmaceutical company, providing the best products and healthcare services with cutting-edge technology to the public is our obligation and responsibility,” she stated in an official release on Saturday (2/5/2026).
In addition to the issuance of new shares, she added, the company is also including warrants as part of the corporate action structure.
The issuance of these warrants is expected to provide added value to shareholders who exercise their rights, while opening up additional capital potential for the company in the future through warrant conversions.
Sinta added that the company targets the rights issue process to proceed gradually, starting from shareholder approval in April 2026 to obtaining the effectiveness statement from the OJK by the end of June 2026.
“Subsequently, the pre-emptive rights exercise period is scheduled to take place in July 2026, with the entire series of corporate actions targeted to be completed in the third quarter of 2026,” she further stated.
“And the creation of long-term value for all stakeholders, in line with good corporate governance principles,” she concluded.